Vabysmo® (Chinese brand name: Luoshijia®) is the commercial brand name of Faricimab Injection, a humanized bispecific monoclonal antibody developed by Roche. It simultaneously targets VEGF-A and Angiopoietin-2 (Ang-2). Via intravitreal injection, it blocks pathological retinal angiogenesis, vascular leakage and inflammatory edema, stabilizes retinal anatomical structure and improves long-term visual acuity. This preparation is exclusively for intravitreal ocular injection only.
Main Indications
Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adult patients;
Treatment of diabetic macular edema (DME) in adult patients;
Treatment of macular edema secondary to retinal vein occlusion (RVO, including CRVO, BRVO and HRVO) in adult patients.
Clinical Research
Global multicenter phase III pivotal trials (TENAYA, LUCERNE, COMINO, BALATON) confirmed that faricimab achieves rapid macular fluid absorption and visual improvement after loading doses, supporting extended maintenance dosing intervals up to 16 weeks to reduce injection frequency compared with single-target anti-VEGF agents;
Registration clinical trials including Chinese subjects verified consistent rapid onset of action, durable anatomical improvement and comparable efficacy and safety profiles against global trial cohorts;
Long-term extension studies conducted at multiple Chinese ophthalmology centers demonstrated sustained efficacy over 3 years with low recurrence of macular edema and favorable long-term ocular tolerability.
Common Side Effects
Severe adverse reactions: Endophthalmitis, anterior uveitis/iritis, vitreous hemorrhage, retinal tear, rhegmatogenous retinal detachment, traumatic cataract, rare systemic thromboembolic events;
Common mild adverse reactions: Conjunctival hemorrhage, transient blurred vision, ocular irritation, corneal abrasion, increased lacrimation, temporary intraocular pressure elevation after injection, cataract progression.
Approval Status in China
Vabysmo® (Faricimab Injection, 6mg/0.05mL per vial, Chinese trade name Luoshijia®) was first approved for marketing in China in December 2023 for diabetic macular edema; additional indication for RVO-related macular edema was approved in October 2024. It is a prescription ophthalmic biological product restricted to intravitreal injection administered by professional ophthalmologists.
Buy Vabysmo (Faricimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
